- Conditions
- Melanoma
- Interventions
- Dabrafenib, Trametinib, Placebos
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 199
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
- Conditions
- Cancer
- Interventions
- GSK2118436 75 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
- Conditions
- Differentiated Thyroid Cancer (DTC)
- Interventions
- Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Dabrafenib, Trametinib, Trametinib placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
- Conditions
- Melanoma
- Interventions
- Spartalizumab, Placebo, Dabrafenib, Trametinib
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 12
- States / cities
- Encinitas, California • Orange, California • San Francisco, California + 9 more